First Time Loading...

Bristol-Myers Squibb Co

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
Price: 59.1 USD -0.1%
Updated: Sep 26, 2023

Intrinsic Value

Intrinsic Value History
Bristol-Myers Squibb Co

Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.

This feature available only with
Unlimited Plan

Sign up to access Bristol-Myers Squibb Co's intrinsic value history.

No restrictions, no limits.
All stocks, all tools.

Spot Contrarian Opportunities

Look for stocks that have been historically overvalued but are now trading below their intrinsic value.

Easily Identify Value Traps

Avoid stocks that are always undervalued and never reach their intrinsic value.

Find Strong Rebounds

Find stocks that have historically corrected quickly from being undervalued to reaching their intrinsic value.

Fundamental Analysis


Balance Sheet Decomposition
Bristol-Myers Squibb Co

Current Assets 28.1B
Cash & Short-Term Investments 8.7B
Receivables 15.1B
Other Current Assets 4.3B
Non-Current Assets 65.4B
Long-Term Investments 2B
PP&E 7.6B
Intangibles 52.5B
Other Non-Current Assets 3.3B
Current Liabilities 20.2B
Accounts Payable 3.1B
Accrued Liabilities 9.3B
Short-Term Debt 606m
Other Current Liabilities 7.2B
Non-Current Liabilities 41.4B
Long-Term Debt 34.7B
Other Non-Current Liabilities 6.7B
Fundamental Scores

BMY Profitability Score
Profitability Due Diligence

Bristol-Myers Squibb Co's profitability score is 62/100. The higher the profitability score, the more profitable the company is.


Bristol-Myers Squibb Co's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

BMY Solvency Score
Solvency Due Diligence

Bristol-Myers Squibb Co's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Short-Term Solvency
Average Altman Z-Score
Average D/E

Bristol-Myers Squibb Co's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BMY Price Targets Summary
Bristol-Myers Squibb Co

Wall Street analysts forecast BMY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BMY is 74.41 USD with a low forecast of 56.56 USD and a high forecast of 94.5 USD.

Price Target
56.56 USD
4% Downside
Price Target
74.41 USD
26% Upside
Price Target
94.5 USD
60% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape


BMY Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

BMY Return Decomposition
Main factors of price return

What is price return decomposition?

BMY Price
Bristol-Myers Squibb Co

1M 1M
6M 6M
1Y 1Y
3Y 3Y
5Y 5Y
10Y 10Y
Annual Price Range
52w Low
52w High
Price Metrics
Average Annual Return 3.73%
Standard Deviation of Annual Returns 16.63%
Max Drawdown -31%
Shares Statistics
Market Capitalization 124B USD
Shares Outstanding 2 100 850 048
Percentage of Shares Shorted 2.1%

BMY News

Last Video News
Bristol-Myers Squibb Co

Other Videos

Last Important Events
Bristol-Myers Squibb Co

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.


Sentiment Analysis
Bristol-Myers Squibb Co

Last 7 Days
Last 30 Days
Last 90 Days

Company Profile

Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co


United States of America



Market Cap

124B USD

Dividend Yield



Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in New York City, New York and currently employs 32,200 full-time employees. The firm is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The firm offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. The Company’s pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company’s products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.


New York City
430 E 29th St Fl 14




32 200


Chairman & CEO
Dr. Giovanni Caforio M.D.
Exec. VP & CFO
Mr. David V. Elkins
Exec. VP & Gen. Counsel
Ms. Sandra Leung Esq.
Exec. VP & Chief Commercialization Officer
Dr. Christopher S. Boerner
Exec. VP and Pres of Research & Early Devel.
Mr. Rupert Vessey BCH, BM, DPHIL, M.A.
Exec. VP and Chief Digital & Technology Officer
Mr. Greg Meyers
Show More
VP & Head of Investor Relations
Mr. Timothy Power
Sr. VP & Chief Compliance and Ethics Officer
Ms. Cari Gallman
Exec. VP & Chief HR Officer
Ms. Ann M. Powell Judge
Head of US Drug Makers - India
Mr. Jitendra Tyagi
Show Less

See Also

Other Stocks
What is the Intrinsic Value of one BMY stock?

The intrinsic value of one BMY stock under the Base Case scenario is 84.95 USD.

Is BMY stock undervalued or overvalued?

Compared to the current market price of 59.1 USD, Bristol-Myers Squibb Co is Undervalued by 30%.